leadf
logo-loader
viewNetScientific PLC
(
AIM:NSCIFRA:NTK1
)

NetScientific hails the potential of investee company's cancer immunotherapy

The latest data points to a 71% response rate to the drug

NetScientific PLC -

NetScientific PLC (LON:NSCI) said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy.

PDS Biotechnology Corporation (NASDAQ:PDSB) will use its presentation at the prestigious American Society of Clinical Oncology (ASCO) annual meeting next month to reveal it has observed a 10-out-of-14, or 71% response rate to lead drug PDS0101.

There was one complete response, in a person with anal cancer, and nine partial responses from this difficult-to-treat grouping. The medication is still working for nine out of 10 patients five months on from first dosing.

The latest data come from a phase II evaluation of the PDS drug, which comes from the company’s Versamune platform. The study is being led by the National Cancer Institute.

NetScientific holds 5.75% of the US-listed company.

The oral presentation takes place on June 7. For more information click here.

Dr Ilian Iliev, chef executive of NetScientific and director of PDS, said: “We are pleased to see the additional data that further demonstrate the efficacy of the novel Versamune platform. It represents the significant potential that PDS0101 has with treating HPV-associated cancers.”

Quick facts: NetScientific PLC

Follow
AIM:NSCI

Price: 113 GBX

Market Cap: £23.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

NetScientific invest £1m in Martlet Capital 'fitting with strategy to...

NetScientific PLC (AIM:NSCI, FRA:NTK1) (AIM:NSCI, FRA:NTK1) chief executive, Dr Ilian Iliev joins Proactive after announcing their news to invest an initial £1mln in Martlet Capital, which has been set up to acquire a portfolio of minority interests in growth companies operating in the Cambridge...

6 days, 16 hours ago

2 min read